{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "858",
          "alt": "R117",
          "position": "858"
        },
        "variant_string_id": "PARK2_858R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "PARK2 mutations decrease E3 ligase activity, leading to cyclin E ubiquitination and mitotic instability.",
          "judgment": "Yes",
          "reasoning": "Extracted from the paper's findings about tumor suppressor function in PARK2 mutations."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays targeting proteasome-mediated degradation and ubiquitination pathways are relevant to PARK2 function.",
          "judgment": "Yes",
          "reasoning": "Derived from the paper's emphasis on functional assays related to tumor suppressor activity."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls (wild-type and mutant variants) were used in the experiments.",
          "judgment": "Yes",
          "reasoning": "Standardized controls ensure applicability to the functional assessment."
        },
        {
          "next_step_or_outcome": "Step 4"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "PARK2 mutations in human malignancies contribute to oncogenesis, as they suppress tumor suppressor activity and promote cyclin E degradation, indicating pathogenic relevance."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "117",
          "alt": "H858",
          "position": "117"
        },
        "variant_string_id": "PARK2_H858H"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Benign variants in PARK2 contribute to tumor suppression, as seen in germline mutations.",
          "judgment": "Yes",
          "reasoning": "Derived from the paper's discussion of benign mutations in the context of PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays targeting ubiquitination and proteasome degradation are applicable to PARK2.",
          "judgment": "Yes",
          "reasoning": "Standardized assays used in the context of tumor suppression."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Control variants (wild-type and mutant) were used in the experiments.",
          "judgment": "Yes",
          "reasoning": "Standardized controls ensure applicability to the functional assessment."
        },
        {
          "next_step_or_outcome": "Step 4"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "Benign mutations in PARK2 contribute to tumor suppression, as seen in germline mutations, indicating moderate pathogenicity."
    }
  ]
}